Drugs / Ad-sig-hMUC-1/ecdCD40L
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00706615 | Jul 2008 → Apr 2009 | breast cancer | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-sig-hMUC-1/ecdCD40L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00706615 ↗ |
| Modality | Vaccine | “An Injectable Replication-Incompetent Adenoviral Vector Vaccine” NCT00706615 ↗ |
| Route | Subcutaneous | “Patients receive MUC-1 vector vaccine subcutaneously on day 0.” NCT00706615 ↗ |